Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID 2019 vaccine - Shenzhen Kangtai Biological Products

Next Previous
X
Search
Drug Profile

COVID 2019 vaccine - Shenzhen Kangtai Biological Products

Alternative Names: BIOKANGTAI COVID-19 Vaccine; KconecaVac; Recombinant ChAdOx1-S; SARS-CoV-2 vaccine - Shenzhen Kangtai Biological Products; Vero Cells - Shenzhen Kangtai Biological Products

Latest Information Update: 10 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Kangtai Biological Products
  • Developer Beijing Minhai Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention; Shenzhen Kangtai Biological Products; Yong Tai Berhad
  • Class COVID-19 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 31 Oct 2021 Registered for COVID-2019 infections (Prevention) in Indonesia (IM)
  • 19 Aug 2021 Shenzhen Kangtai Biological Products, Beijing Minhai Biotechnology and Hunan Province Centers for Disease Control and Prevention plans a phase I trial for COVID-2019 infections (Prevention, In children, In adolescent) in China (IM, Injection) in August 2021 (NCT05003479)
  • 18 Aug 2021 Shenzhen Kangtai Biological Products, Beijing Minhai Biotechnology and Hunan Province Centers for Disease Control and Prevention plans a phase II trial for COVID-2019 infections (Prevention, In children, In adolescents) in China (IM) in September 2021 (NCT05003466)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top